Allogeneic hematopoietic cell transplantation for adult T cell acute lymphoblastic leukemia Journal Article
| Authors: | Hamilton, B. K.; Rybicki, L.; Abounader, D.; Adekola, K.; Advani, A.; Aldoss, I.; Bachanova, V.; Bashey, A.; Brown, S.; DeLima, M.; Devine, S.; Flowers, C. R.; Ganguly, S.; Jagasia, M.; Kennedy, V. E.; Kim, D. D. H.; McGuirk, J.; Pullarkat, V.; Romee, R.; Sandhu, K.; Smith, M.; Ueda, M.; Viswabandya, A.; Vu, K.; Wall, S.; Zeichner, S. B.; Perales, M. A.; Majhail, N. S. |
| Article Title: | Allogeneic hematopoietic cell transplantation for adult T cell acute lymphoblastic leukemia |
| Abstract: | Allogeneic hematopoietic cell transplantation (HCT) is recommended for patients with T cell acute lymphoblastic leukemia (T-ALL) in second or later complete remission (CR) and high-risk patients in first CR. Given its relative rarity, data on outcomes of HCT for T-ALL are limited. We conducted a multicenter retrospective cohort study using data from 208 adult patients who underwent HCT between 2000 and 2014 to describe outcomes of allogeneic HCT for T-ALL in the contemporary era. The median age at HCT was 37 years, and the majority of patients underwent HCT in CR, using total body irradiation (TBI)-based myeloablative conditioning regimens. One-quarter of the patients underwent alternative donor HCT using a mismatched, umbilical cord blood, or haploidentical donor. With a median follow up of 38 months, overall survival at 5 years was 34%. The corresponding cumulative incidence of non-relapse mortality and relapse was 26% and 41%, respectively. In multivariable analysis, factors significantly associated with overall survival were the use of TBI (HR, 0.57; P =.021), age >35 years (HR, 1.55; P =.025), and disease status at HCT (HR, 1.98; P =.005 for relapsed/refractory disease compared with CR). Relapse was the most common cause of death (58% of patients). Allogeneic HCT remains a potentially curative option in selected patients with adult T-ALL, although relapse is a major cause of treatment failure. © 2017 The American Society for Blood and Marrow Transplantation |
| Keywords: | survival; acute lymphoblastic leukemia; hematopoietic cell transplantation; t cell; allogeneic; relapse-free survival |
| Journal Title: | Biology of Blood and Marrow Transplantation |
| Volume: | 23 |
| Issue: | 7 |
| ISSN: | 1083-8791 |
| Publisher: | Elsevier Inc. |
| Date Published: | 2017-07-01 |
| Start Page: | 1117 |
| End Page: | 1121 |
| Language: | English |
| DOI: | 10.1016/j.bbmt.2017.04.003 |
| PROVIDER: | scopus |
| PUBMED: | 28396160 |
| PMCID: | PMC5549947 |
| DOI/URL: | |
| Notes: | Article -- Export Date: 3 July 2017 -- Source: Scopus |
Altmetric
Citation Impact
BMJ Impact Analytics
Related MSK Work